PFS and OS benefits over chemotherapy were maintained for more than 2 years, and many patients had durable responses to ...

A guardian molecule ensures that liver cells do not lose their identity. The discovery is of great interest for cancer medicine because a change of identity of cells has come into focus as a ...

Hepatocellular carcinoma (HCC) is one of the deadliest malignant tumors in the world, and its incidence and mortality have ...

Hepatocellular carcinoma (HCC) is one of the deadliest cancers globally, with increasing incidence and mortality rates.

Third-line enfortumab vedotin improved outcomes in metastatic urothelial carcinoma, per real-world data from the EV-301 trial ...

Among patients in the real world with unresectable or metastatic urothelial carcinoma, Padcev significantly improved overall ...

TheraBionic is the only FDA-approved therapy indicated in liver cancer patients that fail first-line and second-line therapy, so that's really the place it takes right now in 2025. Patients can ...

Padcev plus Keytruda was found to maintain benefit over chemotherapy in untreated locally advanced or metastatic urothelial ...

Dutch health insurers have stopped fully covering two of three medicines for metastatic hormonal breast cancer. Since January ...

Amezalpat has been granted FDA fast track designation as treatment for patients with hepatocellular carcinoma.

(UroToday.com) The 2025 GU ASCO annual meeting featured a prostate cancer session and a presentation by Joseph Allen discussing PSA response and survival based on metastatic site in patients with ...